Validation, based on the capacity of hits to lower huntingtin protein at non-toxic concentrations, was performed in two tiers, first, using HEK293 cells and lymphoblasts from HD patients; and second, using HD patient ESCs and iPSCs, and primary neurons from an HD mouse model. The gene discussed is HTT; the disease is Huntington disease.